Biomarkers · Inflammation
Soluble Tumor Necrosis Factor Receptor 1 (sTNFR1)
Lower values go with lower risk of death. No risk curve catalogued yet.
Published risk of death1.80×highest quartile (Q4) vs lowest quartile (Q1) of sTNFR1 (95% CI 1.40–2.40) · Northern Manhattan Study (NOMAS), multi-ethnic community-based cohort, mean age 69.2 years, New York
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in sTNFR1, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Atorvastatin 10 mg daily vs placebo (crossover) in patients with NYHA II-III heart failure and LVEF <40% | sTNFR1 fell 132 pg/mL (8%) with atorvastatin vs placebo (p = 0.04) in a 16-week crossover trial; period length not stated, duration not stated; n=22 | RCT | Mozaffarian D, et al. Am J Cardiol. 2005;96(12):1699-1704. |